Immunotherapy Neuroblastoma model Combinations aggressive therapy radiotherapy primary tumor site dose intensive chemotherapy metastases complete remissions patients stage IV neuroblastomas virtue tumor specificity use immunotherapy time microscopic residual disease present great promise tumors Monoclonal antibodies high concentrations neuroblastomas potential complement activation inflammation tumor site Hematopoietic factors cytokines body tumoricidal leukocytes Ex vivo activation autologous white cells genetic manipulation tumor-seeking vehicles useful knowledge tumor host immunobiology accumulates optimal combination approaches apparent 